[{"id":"736082c4-cb8f-4038-ae24-2c9486718043","acronym":"BP41072","url":"https://clinicaltrials.gov/study/NCT04077723","created_at":"2021-01-18T19:58:08.759Z","updated_at":"2025-02-25T13:39:56.985Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT04077723 - BP41072","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD20 expression • CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • englumafusp alfa (RG6076)"],"overall_status":"Recruiting","enrollment":" Enrollment 498","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-21"},{"id":"0a2b6dbc-36dd-467c-bb46-4e7fcb611199","acronym":"CO41942","url":"https://clinicaltrials.gov/study/NCT04246086","created_at":"2023-03-27T23:03:02.854Z","updated_at":"2025-02-25T15:34:35.235Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma","source_id_and_acronym":"NCT04246086 - CO41942","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 237","initiation":"Initiation: 08/12/2020","start_date":" 08/12/2020","primary_txt":" Primary completion: 10/15/2028","primary_completion_date":" 10/15/2028","study_txt":" Completion: 10/15/2030","study_completion_date":" 10/15/2030","last_update_posted":"2025-02-10"},{"id":"2dc4eb4c-eda6-4d7f-bf25-c974b4ee8106","acronym":"CO43805","url":"https://clinicaltrials.gov/study/NCT05169515","created_at":"2021-12-27T15:54:16.180Z","updated_at":"2025-02-25T15:27:09.973Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05169515 - CO43805","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • iberdomide (CC-220) • Columvi (glofitamab-gxbm) • golcadomide (CC-99282)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 03/07/2027","primary_completion_date":" 03/07/2027","study_txt":" Completion: 03/07/2029","study_completion_date":" 03/07/2029","last_update_posted":"2025-02-10"},{"id":"dba621d0-4a3a-4b6c-9b33-c48c7ade782a","acronym":"iMATRIX GLO","url":"https://clinicaltrials.gov/study/NCT05533775","created_at":"2022-09-09T15:55:02.207Z","updated_at":"2025-02-25T15:27:37.954Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05533775 - iMATRIX GLO","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 03/30/2027","primary_completion_date":" 03/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2025-02-10"},{"id":"302e12e8-3d06-4205-8871-3fc4c45bd55f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01856192","created_at":"2021-01-18T08:17:29.922Z","updated_at":"2025-02-25T16:43:43.231Z","phase":"Phase 2","brief_title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT01856192","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • MYC • CD20 • CD4","pipe":" | ","alterations":" CD20 expression • MYC translocation","tags":["ALK • MYC • CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 349","initiation":"Initiation: 08/27/2013","start_date":" 08/27/2013","primary_txt":" Primary completion: 03/26/2020","primary_completion_date":" 03/26/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"3e01dea9-3971-4487-84c5-6452884a557d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00972478","created_at":"2021-01-18T03:47:26.597Z","updated_at":"2025-02-25T16:36:04.200Z","phase":"Phase 1/2","brief_title":"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT00972478","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Zolinza (vorinostat) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 11/15/2010","start_date":" 11/15/2010","primary_txt":" Primary completion: 12/30/2015","primary_completion_date":" 12/30/2015","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"9eacdbab-1a64-457b-a4b2-200a00018493","acronym":"GPL study","url":"https://clinicaltrials.gov/study/NCT05335018","created_at":"2022-04-19T22:56:54.403Z","updated_at":"2025-02-25T12:38:12.292Z","phase":"Phase 2","brief_title":"GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT05335018 - GPL study","lead_sponsor":"Seoul National University Hospital","biomarkers":" BCL6","pipe":" | ","alterations":" CD20 expression","tags":["BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Columvi (glofitamab-gxbm) • poseltinib (HM71224)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 05/30/2022","start_date":" 05/30/2022","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-12-16"},{"id":"98bf47af-2f07-41d0-8aba-0ad0045bf73a","acronym":"CHRONOS-1","url":"https://clinicaltrials.gov/study/NCT01660451","created_at":"2021-01-18T07:10:10.841Z","updated_at":"2025-02-25T17:20:13.895Z","phase":"Phase 2","brief_title":"Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas","source_id_and_acronym":"NCT01660451 - CHRONOS-1","lead_sponsor":"Bayer","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aliqopa (copanlisib)"],"overall_status":"Completed","enrollment":" Enrollment 227","initiation":"Initiation: 11/19/2012","start_date":" 11/19/2012","primary_txt":" Primary completion: 06/22/2016","primary_completion_date":" 06/22/2016","study_txt":" Completion: 05/18/2023","study_completion_date":" 05/18/2023","last_update_posted":"2024-07-17"},{"id":"d7a99f87-af15-49c9-a79c-a263479ceeab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05219513","created_at":"2022-02-05T18:28:39.448Z","updated_at":"2024-07-02T16:34:26.627Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05219513","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD20 expression • CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • RG6333"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/18/2022","start_date":" 02/18/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-06-13"},{"id":"d6470e31-1ef9-400d-8e4a-687104d9ddb3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03277729","created_at":"2021-01-18T16:11:11.702Z","updated_at":"2024-07-02T16:34:26.876Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas","source_id_and_acronym":"NCT03277729","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" BCL2","pipe":" | ","alterations":" CD20 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • MB-106"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 12/05/2017","start_date":" 12/05/2017","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 11/16/2037","study_completion_date":" 11/16/2037","last_update_posted":"2024-06-12"},{"id":"24c91644-22bc-4249-aaa6-106bdc7c0471","acronym":"","url":"https://clinicaltrials.gov/study/NCT03524235","created_at":"2021-01-18T17:21:46.884Z","updated_at":"2024-07-02T16:34:59.315Z","phase":"Phase 1","brief_title":"Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL","source_id_and_acronym":"NCT03524235","lead_sponsor":"Noah Merin","biomarkers":" MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression","tags":["MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/18/2018","start_date":" 07/18/2018","primary_txt":" Primary completion: 11/07/2021","primary_completion_date":" 11/07/2021","study_txt":" Completion: 11/01/2031","study_completion_date":" 11/01/2031","last_update_posted":"2024-06-04"},{"id":"30181726-4a7a-4641-822a-3105dcd88382","acronym":"","url":"https://clinicaltrials.gov/study/NCT05303792","created_at":"2022-03-31T17:52:41.961Z","updated_at":"2024-07-02T16:35:01.827Z","phase":"Phase 2","brief_title":"Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT05303792","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD20 • CD22","pipe":" | ","alterations":" CD20 expression • CD22 positive","tags":["CD20 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/27/2023","start_date":" 02/27/2023","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-05-23"},{"id":"90e45678-84d1-4b47-a66b-d3af7d734dab","acronym":"MorningSun","url":"https://clinicaltrials.gov/study/NCT05207670","created_at":"2022-01-26T13:53:53.735Z","updated_at":"2024-07-02T16:35:02.328Z","phase":"Phase 2","brief_title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","source_id_and_acronym":"NCT05207670 - MorningSun","lead_sponsor":"Genentech, Inc.","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 345","initiation":"Initiation: 02/01/2022","start_date":" 02/01/2022","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2024-05-21"},{"id":"18ee0f81-3adf-4bd7-8334-4d0c4101af0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886036","created_at":"2023-11-15T20:15:29.821Z","updated_at":"2024-07-02T16:35:07.221Z","phase":"Phase 2","brief_title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma","source_id_and_acronym":"NCT05886036","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • PD-1 • PD-L2","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • PD-1 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Lunsumio (mosunetuzumab-axgb) • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/23/2024","start_date":" 01/23/2024","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2024-04-29"},{"id":"f0a52ee0-440d-49ea-b590-78924884d90a","acronym":"NP40126","url":"https://clinicaltrials.gov/study/NCT03467373","created_at":"2021-01-18T17:05:19.784Z","updated_at":"2024-07-02T16:35:07.282Z","phase":"Phase 1","brief_title":"A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL","source_id_and_acronym":"NCT03467373 - NP40126","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 03/13/2018","start_date":" 03/13/2018","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2024-04-26"},{"id":"24c3c78a-e1db-479c-9eeb-d51b3073b8a7","acronym":"r/r B-NHL","url":"https://clinicaltrials.gov/study/NCT06364852","created_at":"2024-04-15T18:25:43.339Z","updated_at":"2024-07-02T16:35:09.799Z","phase":"Phase 1","brief_title":"An Evaluation of LY007 Cell Injection for r/r B-NHL","source_id_and_acronym":"NCT06364852 - r/r B-NHL","lead_sponsor":"Ruijin Hospital","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY007"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/25/2021","start_date":" 12/25/2021","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-04-15"},{"id":"59ce27ae-769a-4818-90df-fa3d4bf1853a","acronym":"NP39488","url":"https://clinicaltrials.gov/study/NCT03533283","created_at":"2021-01-18T17:24:16.887Z","updated_at":"2024-07-02T16:35:09.948Z","phase":"Phase 1/2","brief_title":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT03533283 - NP39488","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 05/08/2018","start_date":" 05/08/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-04-12"},{"id":"c3f67f74-ef3d-40b9-bda8-c2b58e4682ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04836195","created_at":"2021-04-08T13:52:40.387Z","updated_at":"2024-07-02T16:35:11.754Z","phase":"Phase 1","brief_title":"Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma","source_id_and_acronym":"NCT04836195","lead_sponsor":"Pacylex Pharmaceuticals","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zelenirstat (PCLX-001)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 10/28/2024","primary_completion_date":" 10/28/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-03"},{"id":"341bd1dd-ae91-47b3-a8bb-d90e76eb4052","acronym":"BYON4228.001","url":"https://clinicaltrials.gov/study/NCT05737628","created_at":"2023-02-21T15:01:28.796Z","updated_at":"2024-07-02T16:35:13.672Z","phase":"Phase 1","brief_title":"First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228","source_id_and_acronym":"NCT05737628 - BYON4228.001","lead_sponsor":"Byondis B.V.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Truxima (rituximab-abbs) • BYON4228"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/04/2024","start_date":" 03/04/2024","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-20"},{"id":"d8a4d573-54c5-44f7-aa60-0be67e158582","acronym":"LYMA-101","url":"https://clinicaltrials.gov/study/NCT02896582","created_at":"2021-01-18T14:12:53.282Z","updated_at":"2024-07-02T16:35:14.422Z","phase":"Phase 2","brief_title":"Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance","source_id_and_acronym":"NCT02896582 - LYMA-101","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" CD20 • CCND1 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CD20 expression • CCND1 expression","tags":["CD20 • CCND1 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CD20 expression • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cytarabine • Gazyva (obinutuzumab) • etoposide IV • dexamethasone • carmustine • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-03-15"},{"id":"099bccbb-36d2-4595-985a-23305468fb81","acronym":"r/r B-NHL","url":"https://clinicaltrials.gov/study/NCT06279611","created_at":"2024-02-29T02:32:51.155Z","updated_at":"2024-07-02T16:35:17.125Z","phase":"Phase 1","brief_title":"An Evaluation of LY007 Cell Injection for r/r B-NHL","source_id_and_acronym":"NCT06279611 - r/r B-NHL","lead_sponsor":"Shanghai Longyao Biotechnology Inc., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY007"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/25/2021","start_date":" 12/25/2021","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-02-28"},{"id":"412d5cd2-47b4-4518-9ce1-4e2f34ef6a7b","acronym":"BrUOG 401","url":"https://clinicaltrials.gov/study/NCT04792502","created_at":"2021-03-11T12:53:42.451Z","updated_at":"2024-07-02T16:35:18.890Z","phase":"Phase 2","brief_title":"Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma","source_id_and_acronym":"NCT04792502 - BrUOG 401","lead_sponsor":"Brown University","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 07/14/2022","start_date":" 07/14/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-02-19"},{"id":"d5be950f-3675-484f-9cf0-33481c11c95d","acronym":"NCI-2011-03562","url":"https://clinicaltrials.gov/study/NCT01527149","created_at":"2021-01-18T06:26:25.305Z","updated_at":"2024-07-02T16:35:20.370Z","phase":"Phase 2","brief_title":"Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT01527149 - NCI-2011-03562","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD20 • CCND1 • IGH • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CD20 expression","tags":["CD20 • CCND1 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • dexamethasone • Arzerra (ofatumumab) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 12/06/2011","start_date":" 12/06/2011","primary_txt":" Primary completion: 04/26/2018","primary_completion_date":" 04/26/2018","study_txt":" Completion: 01/11/2024","study_completion_date":" 01/11/2024","last_update_posted":"2024-02-07"},{"id":"67568ce3-158c-482e-b3ea-065eb7e45343","acronym":"","url":"https://clinicaltrials.gov/study/NCT02628405","created_at":"2021-01-18T12:46:39.314Z","updated_at":"2024-07-02T16:35:21.751Z","phase":"Phase 1/2","brief_title":"R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT02628405","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • lenalidomide • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 05/20/2016","start_date":" 05/20/2016","primary_txt":" Primary completion: 09/24/2021","primary_completion_date":" 09/24/2021","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2024-01-30"}]